Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (981-990 of 1,281) with videos related to

Pageof 129
Sort By:
Journal of Medical Virology|December 18, 2001
Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adultsJ L Sanchez, L N Binn, B L Innis, et al.
Breast Cancer Research : BCR|August 24, 2017
Combining quantitative and qualitative breast density measures to assess breast cancer riskKarla Kerlikowske, Lin Ma, Christopher G Scott, et al.
Lung Cancer (Amsterdam, Netherlands)|August 22, 2013
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)M Neil Reaume, Natasha B Leighl, Nicole Mittmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerM-S Tsao, G Le Teuff, F A Shepherd, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2021
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapySally C M Lau, Christopher Poletes, Lisa W Le, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
ACS Chemical Biology|January 23, 2020
Characterization of Arylalkylamine <i>N</i>-Acyltransferase from <i>Tribolium castaneum</i>: An Investigation into a Potential Next-Generation Insecticide TargetBrian G O'Flynn, Eric M Lewandowski, Karin Claire Prins, et al.
Cancers|May 14, 2022
Bone Progenitors Pull the Strings on the Early Metabolic Rewiring Occurring in Prostate Cancer CellsPablo Sanchis, Nicolas Anselmino, Sofia Lage-Vickers, et al.
Cancer Research Communications|November 6, 2023
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate CancerEmanuela Gentile, Andrew W Hahn, Jian H Song, et al.
Cancer|December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studiesMyung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
Pageof 129

Showing results (981-990 of 1,281) with videos related to

Sort By:
Pageof 129
Journal of Medical Virology|December 18, 2001
Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adultsJ L Sanchez, L N Binn, B L Innis, et al.
Breast Cancer Research : BCR|August 24, 2017
Combining quantitative and qualitative breast density measures to assess breast cancer riskKarla Kerlikowske, Lin Ma, Christopher G Scott, et al.
Lung Cancer (Amsterdam, Netherlands)|August 22, 2013
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)M Neil Reaume, Natasha B Leighl, Nicole Mittmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerM-S Tsao, G Le Teuff, F A Shepherd, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2021
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapySally C M Lau, Christopher Poletes, Lisa W Le, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
ACS Chemical Biology|January 23, 2020
Characterization of Arylalkylamine <i>N</i>-Acyltransferase from <i>Tribolium castaneum</i>: An Investigation into a Potential Next-Generation Insecticide TargetBrian G O'Flynn, Eric M Lewandowski, Karin Claire Prins, et al.
Cancers|May 14, 2022
Bone Progenitors Pull the Strings on the Early Metabolic Rewiring Occurring in Prostate Cancer CellsPablo Sanchis, Nicolas Anselmino, Sofia Lage-Vickers, et al.
Cancer Research Communications|November 6, 2023
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate CancerEmanuela Gentile, Andrew W Hahn, Jian H Song, et al.
Cancer|December 5, 2018
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studiesMyung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, et al.
Pageof 129